Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CAREFUSION Corp | d579512dex991.htm |
| 8-K - FORM 8-K - CAREFUSION Corp | d579512d8k.htm |
 Exhibit 99.2
©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
|
 Forward-Looking
Statements 2
©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
“Safe
Harbor”
Statement
under
the
Private
Securities
Litigation
Reform
Act
of
1995:
This
presentation
contains
our
fiscal
2014
financial
guidance,
which
are
forward-looking
statements
addressing
expectations,
prospects,
estimates
and
other
matters
that
are
dependent
upon
future
events
or
developments.
The
matters
discussed
in
these
forward-looking
statements
are
subject
to
risks
and
uncertainties
that
could
cause
actual
results
to
differ
materially
from
those
projected,
anticipated
or
implied.
The
most
significant
of
these
uncertainties
are
described
in
CareFusion’s
Form
10-K,
Form
10-Q
and
Form
8-K
reports
(including
all
amendments
to
those
reports)
and
exhibits
to
those
reports,
and
include
(but
are
not
limited
to)
the
following:
we
may
be
unable
to
effectively
enhance
our
existing
products
or
introduce
and
market
new
products
or
may
fail
to
keep
pace
with
advances
in
technology;
we
are
subject
to
complex
and
costly
regulation;
cost
containment
efforts
of
our
customers,
purchasing
groups,
third-party
payers
and
governmental
organizations
could
adversely
affect
our
sales
and
profitability;
current
economic
conditions
have
and
may
continue
to
adversely
affect
our
results
of
operations
and
financial
condition;
we
may
be
unable
to
realize
any
benefit
from
our
cost
reduction
and
restructuring
efforts
and
our
profitability
may
be
hurt
or
our
business
otherwise
might
be
adversely
affected;
we
may
be
unable
to
protect
our
intellectual
property
rights
or
may
infringe
on
the
intellectual
property
rights
of
others;
defects
or
failures
associated
with
our
products
and/or
our
quality
system
could
lead
to
the
filing
of
adverse
event
reports,
recalls
or
safety
alerts
and
negative
publicity
and
could
subject
us
to
regulatory
actions;
and
we
are
currently
operating
under
an
amended
consent
decree
with
the
FDA
and
our
failure
to
comply
with
the
requirements
of
the
amended
consent
decree
may
have
an
adverse
effect
on
our
business.
This
presentation
reflects
management’s
views
as
of
August
8,
2013.
Except
to
the
limited
extent
required
by
applicable
law,
CareFusion
undertakes
no
obligation
to
update
or
revise
any
forward-looking
statements,
whether
as
a
result
of
new
information,
future
events
or
otherwise. |
 3
Fiscal 2014 Guidance
August 8, 2013
FY14 Guidance
Total Revenue (constant currency)
1-4%
Medical Systems Revenue (constant currency)
1-4%
Procedural Solutions Revenue (constant currency)
2-4%
Adjusted Operating Margin¹
21-22%
Adjusted Effective Tax Rate¹
28-30%
Adjusted Diluted EPS From Continuing Operations¹
$2.30-$2.40
Diluted Weighted Average Shares Outstanding²
~215 million
Operating Cash Flow
$500-$550 million
Capital Expenditures
~$110 million
©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
1
Adjusted
amounts
are
non-GAAP
financial
measures.
These
measures
exclude
amortization
of
acquired
intangible
assets,
nonrecurring
restructuring
and
acquisition
integration
charges,
and
the
tax
effects
of
these
items.
A
GAAP
to
non-GAAP
reconciliation
can
be
found
in
the
company’s
Q4FY13
earnings
release,
which
was
furnished
to
the
SEC
on
Form
8-K
on
August
8,
2013
and
is
posted
on
CareFusion’s
website
at
www.carefusion.com
under
the
Investors
tab.
The
Form
8-K
also
includes
a
discussion
of
the
reasons
why
management
believes
that
the
presentation
of
non-GAAP
financial
measures
provides
useful
information
to
investors
regarding
the
company’s
financial
condition
and
results
of
operations.
2
On
August
8,
2013
CareFusion
announced
a
$750
million
share
repurchase
program.
Outlook
for
diluted
weighted
average
shares
outstanding
reflects
the
impact
of
expected
repurchases
during
fiscal
2014. |
 Conversion
markets provide
additional
growth
CFN markets
grow low
single digits
Base market
growth
M&A
Share gain
2012 Adjusted
Diluted EPS¹
2015 Adjusted
Diluted EPS¹
Margin mix
Operational
efficiencies
Revenue Growth
$1.95
$1B+ of
acquisition
spend
Operational
efficiency
initiatives
Mix shift to
higher margin
products
$1B+ share
repurchase²
12 -14%
CAGR
1
2012
Adjusted
Diluted
EPS
reflects
GAAP
EPS
of
$1.60
as
reported
in
the
Company’s
fiscal
2012
Form
10-K,
as
adjusted
for
nonrecurring
restructuring
and
acquisition
integration
charges
($0.16),
amortization
of
acquired
intangible
assets
($0.22),
spinoff
related
items
($0.02),
and
offset
by
the
tax
effect
of
these
items
($0.04).
As
EPS
calculations
are
performed
separately
for
each
component,
the
sum
of
the
per
share
components
may
not
equal
the
per
share
amounts
presented.
2
In
June
2013,
the
Company
completed
its
initial
$500
million
share
repurchase
authorization
announced
in
February
2012.
On
August
8,
2013
the
Company
announced
a
new
$750
million
share
repurchase
authorization.
Share
repurchases
in
excess
of
the
existing
authorization
are
subject
to
board
of
directors
approval.
Three year roadmap
4
Operating Margin
Expansion
Share
repurchase
©
2013 CareFusion Corporation or one of its subsidiaries. All rights reserved.
|